All In Biotech

NDA 210884 · Tonix Meds

Tosymra

Sumatriptan · Nasal · Serotonin-1b and Serotonin-1d Receptor Agonist

Last checked: Nov 20, 2026Latest source record: Jan 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jan 25, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

113

33 Phase 3, 5 recruiting

FAERS reports

18,395

11,313 serious, 585 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established ( 1 ) Not indicated for the preventive treatment of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with TOSYMRA, reconsider the diagnosis before TOSYMRA is administered to treat any subsequent attacks. TOSYMRA is not indicated for the preventive treatment of migraine. TOSYMRA is not indicated for the treatment of cluster headache.

Mechanism: Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TOSYMRA · SUMATRIPTAN 10MG/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.

All 113 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,839
  • headache1,501
  • migraine1,273
  • nausea1,260
  • fatigue1,073
  • dizziness887
  • pain851
  • off label use838
  • vomiting720
  • dyspnoea658
  • diarrhoea648
  • anxiety613

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200512
20062
20074
200820
200946
201083
2011100
2012334
2013371
2014554
2015790
20161,137
20171,168
20181,728
20191,878
20201,637
20211,524
20221,432
20231,642
20241,340
20251,445
20261,132

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tosymra (Sumatriptan)

2024 spending

$382K

Beneficiaries

173

473 claims

Per beneficiary

$2,208

$107.19 per unit

View as table
YearSpending
2020$0
2021$22,593
2022$428,134
2023$492,449
2024$381,934

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: Tonix Meds

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.